Cures Within Reach Names Eli Lilly and Company as Recipient of its 2021 Patient Impact Industry Award
Lilly joins ReFRAME at Scripps Research/Calibr and CURE ID at the FDA and NCATS/NIH
CHICAGO - June 8, 2021 - PRLog -- Cures Within Reach today announced Eli Lilly and Company as the recipient of the 2021 Patient Impact Industry Award, part of its Global Health Repurposing Awards. The award recognizes Lilly's work to treat COVID-19 patients using medication that is already approved for other treatments, among other diseases.
Cures Within Reach celebrates and honors Lilly's ongoing commitment to improving the lives of patients with unmet medical needs. During the COVID-19 pandemic, this has been through its support of baricitinib, an existing rheumatoid arthritis medication, to treat certain hospitalized COVID-19 patients, among other initiatives. Baricitinib has been authorized for emergency use by the FDA in combination with remdesivir.
"Like many around the world, Lilly has worked tirelessly since the start of the pandemic to help those impacted by COVID-19," said Robert Baker, Lilly's Deputy Chief Medical Officer. "These efforts included evaluating the potential of our existing medicines to treat complications of COVID-19. We are honored to be recognized by Cures Within Reach for using our medicines to address unmet needs and significantly impact patients' lives."
In addition, Lilly has continued to test already approved therapies for new indications, including duloxetine for fibromyalgia and ramucirumab for various cancers after it was first approved for stomach cancer.
Earlier this year, Cures Within Reach announced two other winners of its 2021 Global Health Repurposing Awards. They are:
"These important contributions to improving the quality of life for patients who often feel hopeless should be recognized,"
For more information on these awardees, upcoming events and CWR, visit http://bit.ly/
About Cures Within Reach
Cures Within Reach (CWR) is a US-based philanthropic leader improving patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research: driving more treatments to more patients more quickly. CWR catalyzes research to facilitate and validate already approved therapies for new indications to create clinical impact. CWR isn't funding to the regulatory "finish line," but providing seed funds to achieve catalytic effect. CWR's 2021 initiatives include focused efforts to impact Pediatrics; Veterans; and Diversity, Equity & Inclusion efforts. CWR currently has a global portfolio of 33 repurposing research projects at 28 institutions in 21 diseases. Visit cureswithinreach.org (http://www.cureswithinreach.org/)
Clare Thibodeaux, PhD